← Back to Screener
Soleno Therapeutics, Inc. Common Stock (SLNO)
Price$53.01
Value ScoreD
Growth ScoreA
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)6.07%
Price vs S&P 500 (4W)-4.30%
VGM Score70.60
Market Capitalization$2.76B
P/E Ratio (Annual)132.26x
All Metrics
P/CF (Annual)59.04x
Book Value / Share (Quarterly)$9.59
P/TBV (Annual)5.59x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)298.89%
Cash Flow / Share (Quarterly)$2.04
Price vs S&P 500 (YTD)6.17%
Gross Margin (TTM)98.63%
Net Profit Margin (TTM)33.70%
EPS (TTM)$1.70
10-Day Avg Trading Volume1.80M
EPS Excl Extra (TTM)$1.70
EPS (Annual)$0.40
ROI (Annual)4.18%
Gross Margin (Annual)98.58%
Cash / Share (Quarterly)$4.94
P/E Basic Excl Extra (TTM)28.77x
P/E Normalized (Annual)132.26x
ROA (Last FY)3.71%
Revenue Growth TTM (YoY)2850.00%
EBITD / Share (TTM)$1.62
ROE (5Y Avg)-99.63%
Operating Margin (TTM)30.33%
Cash Flow / Share (Annual)$0.89
P/B Ratio5.57x
P/B Ratio (Quarterly)3.49x
Net Income / Employee (Annual)$114,800
EV / Revenue (TTM)9.40x
Net Interest Coverage (TTM)-63.10x
ROA (TTM)18.26%
EV / EBITDA (TTM)30.29x
EPS Incl Extra (Annual)$0.40
Current Ratio (Annual)5.80x
Quick Ratio (Quarterly)5.22x
3-Month Avg Trading Volume2.82M
52-Week Price Return2548.62%
EV / Free Cash Flow (Annual)57.35x
P/E Incl Extra (TTM)28.77x
Revenue / Employee (TTM)$1,566,000
Tangible BV / Share (Quarterly)$9.50
P/S Ratio (Annual)14.51x
Asset Turnover (Annual)0.34x
52-Week High$90.32
EPS Excl Extra (Annual)$0.40
CapEx CAGR (5Y)48.82%
Tangible BV CAGR (5Y)106.22%
26-Week Price Return14.47%
Quick Ratio (Annual)5.44x
13-Week Price Return42.35%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)5.62x
Enterprise Value$2.68B
Asset Turnover (TTM)0.54x
Book Value / Share Growth (5Y)0.08%
Revenue / Employee (Annual)$1,046,200
Pretax Margin (Annual)10.97%
Cash / Share (Annual)$5.84
3-Month Return Std Dev79.50%
Net Income / Employee (TTM)$527,700
ROE (Last FY)4.64%
Net Interest Coverage (Annual)-32.65x
EPS Basic Excl Extra (Annual)$0.40
P/FCF (TTM)23.41x
Receivables Turnover (TTM)5.90x
EV / Free Cash Flow (TTM)25.42x
Total Debt / Equity (Quarterly)0.10x
EPS Incl Extra (TTM)$1.70
Receivables Turnover (Annual)7.63x
ROI (TTM)20.43%
P/S Ratio (TTM)9.69x
Revenue / Share (Annual)$3.63
Tangible BV / Share (Annual)$8.52
Forward P/E11.44x
Price vs S&P 500 (52W)2239.53%
P/E Ratio (TTM)28.77x
Year-to-Date Return14.49%
5-Day Price Return0.15%
EPS Normalized (Annual)$0.40
ROA (5Y Avg)-49.76%
Net Profit Margin (Annual)10.97%
Month-to-Date Return0.36%
Cash Flow / Share (TTM)$-3.15
EBITD / Share (Annual)$0.22
Operating Margin (Annual)4.94%
LT Debt / Equity (Annual)0.11x
P/CF (TTM)26.18x
ROI (5Y Avg)-97.30%
P/E Excl Extra (TTM)28.77x
LT Debt / Equity (Quarterly)0.10x
EPS Basic Excl Extra (TTM)$1.70
P/TBV (Quarterly)3.52x
P/B Ratio (Annual)5.52x
Inventory Turnover (TTM)0.84x
Pretax Margin (TTM)34.94%
Book Value / Share (Annual)$8.61
Price vs S&P 500 (13W)34.00%
Beta-2.31x
P/FCF (Annual)59.13x
Revenue / Share (TTM)$5.37
ROE (TTM)22.86%
52-Week Low$29.43
vGradeD
gGradeA
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.59est. 0.69
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.32
4.32
4.32
2.69
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLNOSoleno Therapeutics, Inc. Common Stock | D | A | A | $53.01 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Soleno Therapeutics is a biopharmaceutical company developing novel treatments for rare diseases. Its lead product candidate, DCCR (Diazoxide Choline), is a proprietary extended-release formulation designed to activate KATP channels in the brain, pancreas, and fat tissue. The company targets underserved patient populations with significant unmet medical needs.